Results 101 to 110 of about 1,175 (172)

Hormonal contraception after use of ulipristal acetate as emergency contraception: A systematic review. [PDF]

Contraception
Snyder EM, Curtis KM, Nguyen AT, Tadikonda A, Kortsmit K, Zapata LB, Whiteman MK.   +6 more
europepmc   +1 more source

Effects of female hormone withdrawal and ulipristal acetate on MED12 mutation positive and negative uterine leiomyomas using a xenograft model. [PDF]

Sci Rep
Sato S, Sakai T, Tamehisa T, Shiroshita A, Takasaki H, Kajimura T, Tamura I, Maekawa R, Sugino N.   +8 more
europepmc   +1 more source

Assessment of Hepatic Safety of Ulipristal Acetate in Korean Women with Uterine Fibroids: A Real-World Study Using Biochemical Markers. [PDF]

J Clin Med
Park JY, Namkung J, Seo YH, Chung Y.
europepmc   +1 more source

Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial. [PDF]

BMJ Sex Reprod Health
Edelman A, Hennebold JD, Bond K, Lim JY, Cherala G, Blue SW, Kraft SP, Erikson DW, Archer D, Jensen J.   +9 more
europepmc   +1 more source

Pharmacodynamic evaluation of the etonogestrel contraceptive implant initiated midcycle with and without ulipristal acetate: An exploratory study. [PDF]

Contraception
Gawron LM, Kaiser JE, Gero A, Sanders JN, Johnstone EB, Turok DK.   +5 more
europepmc   +1 more source

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel. [PDF]

Contraception
Edelman A, Jensen JT, Brown J, Thomas M, Archer DF, Schreiber CA, Teal S, Westhoff C, Dart C, Blithe DL.   +9 more
europepmc   +1 more source

Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids. [PDF]

Int J Environ Res Public Health, 2020
Szydłowska I, Marciniak A, Nawrocka-Rutkowska J, Rył A, Starczewski A.   +4 more
europepmc   +1 more source

Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic! [PDF]

Eur J Obstet Gynecol Reprod Biol, 2020
Rozenberg S, Revercez P, Fastrez M, Vandromme J, Bucella D.   +4 more
europepmc   +1 more source

The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.

J Clin Endocrinol Metab, 2020
Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S.   +7 more
europepmc   +1 more source

Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial. [PDF]

Obstet Gynecol, 2019
Lukes AS, Soper D, Harrington A, Sniukiene V, Mo Y, Gillard P, Shulman L.   +6 more
europepmc   +1 more source